Medpage Today on MSN

Infrequent Zoledronate Infusions Reduced Vertebral Fractures Soon After Menopause

Intravenous zoledronate (Reclast) administered once every 5 years reduced the incidence of morphometric vertebral fractures ...
Healio

Zoledronate infusion preserves BMD gains after denosumab discontinuation for women with osteoporosis

Please provide your email address to receive an email when new articles are posted on . Discontinuation of denosumab is associated with a rapid return to pretreatment BMD levels and an increased risk ...
Monthly Prescribing Reference

Zoledronate Prevents Morphometric Vertebral Fractures Over 10 Years

The researchers found that 6.3, 6.6, and 11.1% of the zoledronate-zoledronate, zoledronate-placebo, and placebo-placebo groups, respectively, had a new morphometric fracture at follow-up. HealthDay ...
Healio

Zoledronate limits fracture risk in older women with osteopenia

Please provide your email address to receive an email when new articles are posted on . “The need to establish treatment efficacy in osteopenia has become more pressing, given the clinical trend to ...
Medscape

Lower Annual Doses of Zoledronate May Do the Trick

June 7, 2011 (Boston, Massachusetts) — Lower doses than are currently prescribed of the bisphosphonate zoledronate may be enough to increase bone density and reduce bone resorption in postmenopausal ...
Aidsmap

Single dose of intravenous zoledronate shown to treat bone loss effectively for one year

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...
Medscape

Zoledronate Boosts Sclerostin, Which Slows Bone Formation

MESSINA, Italy — Although the bisphosphonate zoledronic acid, or zoledronate (Aclasta, Reclast, Novartis), stops bone loss in patients with osteoporosis, it also ups levels of the protein biomarker ...
Science Daily

Bone loss after denosumab, only partial protection with zoledronate

To counter the decline in BMD after denosumab treatment is discontinued, osteoporosis patients may be transitioned from denosumab to other anti-resorptives. This report investigates whether a single ...
NPR

Wider Use Of Osteoporosis Drug Could Prevent Bone Fractures In More Elderly Women

Editor's note: This story was updated on Oct. 23, to add conflict-of-interest disclosures for the lead author of the research study. A large study has produced strong evidence that a drug commonly ...
CMAJ

Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial

BACKGROUND: Intravenous zoledronate 5 mg annually reduces fracture risk, and 5 mg every 2 years prevents bone loss, but the optimal dosing regimens for these indications are uncertain. METHODS: We ...
JSTOR Daily

Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity

Joo Hwan No, Fernando de Macedo Dossin, Yonghui Zhang, Yi-Liang Liu, Wei Zhu, Xinxin Feng, Jinyoung Anny Yoo, Eunhae Lee, Ke Wang, Raymond Hui, Lucio H. Freitas-Junior, Eric Oldfield Proceedings of ...
Hosted on MSN

Zoledronate Prevents Morphometric Vertebral Fractures Over 10 Years

WEDNESDAY, Jan. 15, 2025 (HealthDay News) -- For early postmenopausal women, zoledronate administered at baseline and five years is effective for preventing morphometric vertebral fracture, according ...